Skip to main content
. 2019 Jun 4;2019:1576359. doi: 10.1155/2019/1576359

Table 1.

Clinical studies using different laser devices for the treatment of UI/GSM.

Author(s) Laser type Primary goal Study type N Outcome Follow-up (months)
Fistonic I, et al. [52] 2012 Er:YAG SMOOTH® SUI Obs 39 3.31 6
Fistonic N, et al. [15] 2015 Er:YAG SMOOTH® SUI Obs 73 51, 38.32 6
Fistonic I, et al. [11] 2015 Er:YAG SMOOTH® SUI Obs 31 5.11, 32.52 6
Ogrinc BU, et al. [17] 2015 Er:YAG SMOOTH® SUI/MUI Obs 175 4.74, 622 12
Gambacciani M, et al. [19] 2015 Er:YAG SMOOTH® SUI/VVA Obs 19 6.41, 113, 6
Leshunov E, et al. [21] 2015 Er:YAG SUI Obs 37 53 1
Khalafalla MM, et al. [53] 2015 Er:YAG SMOOTH® SUI Obs 50   6
Pardo J, et al. [20] 2016 Er:YAG SMOOTH® SUI Obs 42 81, 38.12 6
Tien YW, et al. [18] 2016 Er:YAG SMOOTH® SUI/OAB Obs 35 125, 502 6
Pitsouni E, et al. [25] 2016 CO2 GSM/SUI Obs 35 4.71 4
Perino A, et al.[31] 2016 CO2 OAB Obs 30   1
Isaza GP, et al. [24] 2017 CO2 SUI Obs 161 7.51 36
Gaspar A, et al. [45] 2017 Er:YAG SMOOTH® SUI Obs 22 101, 462 6
Lin YH, et al. [34] 2017 Er:YAG SMOOTH® SUI/OAB Obs 30 4.51 3
Lapii GA, et al. [10] 2017 Er:YAG SMOOTH® SUI Obs 98 Histology 2
Neimark AI, et al. [22] 2018 Er:YAG SMOOTH® SUI Obs 98 732 2
Blaganje M, et al. [23] 2018 Er:YAG SMOOTH® SUI RCT 114 41, 212 3
Gaspar A, et al. [46] 2018 Er:YAG SMOOTH® SUI Obs 29 4.91, 143, 452 6
Fistonic I, et al. [27] 2018 Er:YAG SMOOTH® SUI Obs 85 193 6
Gambacciani M, et al. [19] 2018 Er:YAG SMOOTH® SUI/GSM Obs 114 4.21 12
Okui N [51] 2018 Er:YAG SMOOTH® SUI Pro 50 111, 313 12
Pardo Shanz J, et al. [54] 2018 Er:YAG diode SUI Pro 19 81, 26.32 3
Samuels JB, et al. [55] 2019 CO2 GSM/SUI Obs 25 652 12
Lin YH, et al. [56] 2019 Er:YAG SMOOTH® SUI Obs 41 3.51, 7.13, 36.62 6

SUI, Stress Urinary Incontinence; MUI, Mixed Urinary Incontinence; OAB, Overactive Bladder; VVA, Vulvo-Vaginal Atrophy; GSM, Genito-urinary Syndrome of Menopause.

ICIQ-UI, International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form; ISI, Incontinence Severity Index; KHQ, King's Health Questionnaire; PIFQ-7, Pelvic Floor Impact Questionnaire; OAB-Q SF, Overactive Bladder Questionnaire Short Form; Obs, Observational; RCT, randomized controlled trial; Pro, Prospective Outcomes.

1: Mean ICIQ score reduction; 2: percentage of the continent after follow-up; 3: mean pad test weight reduction (g); 4: mean ISI score reduction; 5: Mean KHQ (King's Health Questionnaire) score reduction.